Head & neck cancers / Clinical Insights 06/05/2026

Defining the Current Landscape in Recurrent Metastatic Head and Neck Cancer

An image of a professional woman with shoulder-length blonde hair, wearing yellow glasses and a black top, against a dark background, representing oncology research and expertise. Barbara Burtness, MD Paul Swiecicki, MD Ari Rosenberg, MD Jessica Geiger, MD Smiling man with beard wearing a white shirt, professional headshot, suitable for oncology or cancer research content, emphasizing healthcare and medical expertise. Rahul Gosain, MD, MBA Oncologist smiling in white coat, highlighting cancer research and treatment expertise, with a bow tie, in a bright medical setting. Rohit Gosain, MD

Key Points

  • Pembrolizumab with or without chemotherapy remains the standard frontline therapy for recurrent metastatic head and neck cancer.
  • Most patients present with recurrence following prior curative-intent therapy rather than de novo metastatic disease.
  • Treatment selection in the frontline setting is guided by PD-L1 expression and clinical factors.
  • The lack of effective options after progression on immunotherapy represents a major unmet need.

A Clinical Insights discussion on metastatic head and neck cancer was held coinciding with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The session was led by Oncology Brothers podcast cohosts Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, and Rahul Gosain, MD, MBA, of Wilmot Cancer Institute. They were joined by a panel consisting of Barbara Burtness, MD, of Yale School of Medicine; Ari Rosenberg, MD, of the University of Chicago; Paul Swiecicki, MD, of University of Michigan Health; and Jessica Geiger, MD, of Cleveland Clinic. 

The discussion opened by framing the current treatment paradigm in recurrent metastatic disease. Dr. Geiger explained that most patients with metastatic head and neck cancer present after prior curative-intent surgery or radiation therapy; de novo metastatic disease is relatively uncommon in this population. She emphasized that pembrolizumab-based therapy has become the foundation of first-line treatment. Depending on PD-L1 expression and clinical factors, treatment may involve monotherapy or combination chemoimmunotherapy. 

Although treatment decisions are individualized, they are informed by findings from KEYNOTE-048, Dr. Geiger said. She explained that KEYNOTE-048 established pembrolizumab as the standard of care in the first-line setting and noted that while immunotherapy has improved outcomes, it has not eliminated disease progression. Many patients eventually require additional lines of therapy, creating a challenging clinical transition point after frontline treatment failure. Durability of response continues to be a key limitation in this disease setting.

Dr. Rosenberg highlighted the significant unmet need that persists after progression on immunotherapy, emphasizing that patients often experience severe symptom burden, including pain and functional impairment. He noted that dysarthria and nutritional challenges are common in advanced disease. Treatment options after progression remain limited to single-agent chemotherapy or cetuximab, which provide modest response rates and limited durability. The panel agreed that this continues to be one of the most difficult spaces in solid tumor oncology.